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Abstract 
Background: Overweight and obesity have been adversely associated with longevity in dogs but there is scarce 
knowledge on the relation between body composition and lifespan. We aimed to investigate the effects of body 
composition, and within-dog changes over time, on survival in adult Labradors using a prospective cohort study 
design. The dogs had a median age of 6.5 years at study start and were kept in similar housing and management con-
ditions throughout. The effects of the various predictors, including the effect of individual monthly-recorded change 
in body weight as a time varying covariate, were evaluated using survival analysis.
Results: All dogs were followed to end-of-life; median age at end-of-life was 14.0 years. Body composition was meas-
ured annually with dual-energy x-ray absorptiometer (DEXA) scans between 6.2 and 17.0  years. All 39 dogs had DEXA 
recorded at 8, 9 and 10 years of age. During the study the mean (± SD) percent of fat (PF) and lean mass (PL) was 32.8 
(± 5.6) and 64.2 (± 5.5) %, respectively, with a mean lean:fat ratio (LFR) of 2.1 (± 0.6); body weight (BW) varied from 
17.5 to 44.0 kg with a mean BW change of 9.9 kg (± 3.0). There was increased hazard of dying for every kg increase in 
BW at 10 years of age; for each additional kg of BW at 10 years, dogs had a 19% higher hazard (HR = 1.19, P = 0.004). 
For the change in both lean mass (LM) and LFR variables, it was protective to have a higher lean and/or lower fat mass 
(FM) at 10 years of age compared to 8 years of age, although the HR for change in LM was very close to 1.0. For age at 
study start, older dogs had an increased hazard. There was no observed effect for the potential confounders sex, coat 
colour and height at shoulders, or of the time-varying covariate.
Conclusions: These results suggest that even rather late-life control efforts on body weight and the relationship 
between lean and fat mass may influence survival in dogs. Such “windows of opportunity” can be used to develop 
healthcare strategies that would help promote an increased healthspan in dogs.
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Background
Most of us recognise that the longevity of our compan-
ion dogs has increased. Figures reported from a 25 years 
period in the United Kingdom (UK) showed that the 
average age of dogs had increased from 4.8 to 6.0 years, 
an increase of 25%; there was also an increase in the pro-
portion of dogs living beyond 8 years from 24 to 34% [1]. 
This improvement in longevity can be explained by sev-
eral factors, including advances in veterinary medicine, 
improvements in nutritional support and owner inter-
est in seeking better veterinary and husbandry care. For 
most owners the thought that their dog could achieve 
an exceptional age, whilst still having a satisfactory qual-
ity of life, is an attractive prospect. In order to maximise 
both the quality and quantity of life experienced, an ulti-
mate aim should be to extend both a dog’s lifespan and 
healthspan, the latter being defined as the period of life 
during which an individual is generally healthy and free 
from serious disease [2].
Dogs provide valuable companionship and contribute 
to enhanced life quality for their owners. In addition, 
dogs provide a model of ageing for humans [3] as they 
share a similar environment, are exposed to the same 
pollutants, receive comparable medical care [3, 4], age 
faster [3] and their ageing is also similar in many ways 
to human ageing [5, 6]. For example, research has been 
undertaken to identify key cellular and biomolecular dys-
functions that drive inflammageing and muscle wasting 
disorders in humans [7] as well as investigating inflam-
mageing, and its intervention, in dogs [8, 9]. Inflammage-
ing is a term used to describe the low-grade, chronic, 
systemic inflammation, in the absence of overt infection 
(“sterile” inflammation), that occurs with ageing [10]. 
The translational aspect of canine ageing as a model for 
human ageing is further captured by the concept of One 
Health, a worldwide strategy for expanding interdiscipli-
nary collaborations and communications in all aspects of 
health care for humans, animals and the environment. 
Although specific diseases, such as Alzheimer’s [11], and 
other factors related to ageing, such as nutritional strate-
gies, have been reported in dogs [12], it is not yet clear 
what other factors may be related to increased longevity.
It has been known for many years, that one of the 
most effective strategies for increasing healthspan across 
numerous species is through calorie restriction [3, 13, 
14]. There are several publications that report on other 
beneficial effects of calorie restriction in dogs; for exam-
ple, a major effect of lifetime calorie restriction on the 
development and progression of osteoarthritis (OA) in 
both hip and elbow joints of Labrador retrievers has been 
shown [15–17]: this seminal study was carried out in the 
USA from 1987 to 2001 and involved a birth cohort of 48 
Labrador puppies randomly assigned to a feeding group 
at 8 weeks of age and followed until end-of-life. The ‘con-
trol’ group (n = 24) was initially fed ad  libitum and then 
fed a reduced amount of food from 3.25  years of age 
onwards to prevent excessive weight gain and based on 
calculations of energy requirements to maintain an ideal 
body weight for a large breed dog, whilst the ‘restricted’ 
group (n = 24) was still fed 25% less than their sex and 
body weight (BW) matched sibling pair. A recent publica-
tion [18] reported and compared median survival times 
(MST) of four groups of Labradors that included the two 
aforementioned groups, a group of 542 privately owned 
UK dogs that died after 3.5 years of age, and as reported 
herein, a cohort study group that followed 39 dogs from 
mid-adulthood to end-of-life and fed with an aim to 
maintain a body condition score (BCS) between 2 and 
4 on a 5-point scale [19]. The cohort of 39 dogs had an 
MST of 14.0 years which was significantly longer than the 
MSTs for the other three groups. The birth cohort experi-
enced an MST of 11.1 years for the ‘control’ group which 
was significantly shorter than the MST of 12.9 years for 
the ‘restricted’ group. The final group, reported from 
the UK survey, showed an MST of 12.6 years which was 
not significantly different from the ‘restricted’ group. 
Other studies of owned Labradors have reported similar 
median ages of 12 years at end-of-life [20–22]. In spite of 
this, detailed knowledge on the long-term effect of calo-
rie restriction on other aspects of healthy ageing, such as 
body composition, is still missing.
Whilst a long healthspan can be enhanced by reduc-
ing the frequency or delaying the onset of diseases such 
as cancer, it has been suggested that a major influence 
in increasing longevity will be to slow down the ageing 
process [3, 23, 24]. The ageing process that leads to a 
decline in function of most organs and tissues, including 
sarcopenia, cognitive decline, diabetes and osteoarthritis 
may be similar in dogs and humans [3]. Sarcopenia, the 
gradual and progressive loss of muscle mass and function 
in absence of disease, is a key process in ageing humans 
[25, 26] and dogs [27, 28]. Research has emphasised the 
importance for humans of maintaining a lean body con-
dition by preserving muscle mass, and losing fat mass, 
to prevent development of lifestyle-related diseases and/
or impaired mobility that negatively impacts a healthy 
life expectancy [29, 30]. In dogs, preliminary results on 
average changes in body composition up to 13  years of 
age have been described for the cohort of 39 Labradors, 
reported on earlier [18, 19], although this did not fol-
low all dogs until end-of-life and the analysis was not 
adjusted for potential confounding variables [19]: dual-
energy x-ray absorptiometer (DEXA) scans revealed 
that the increase in absolute (kg) fat mass (FM) was sig-
nificantly lower for dogs surviving ≥ 13 to ≤ 15.5  years 
of age compared with dogs that died before they reached 
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13 years, whilst all dogs lost a similar but non-significant 
amount of absolute lean mass (LM). Dogs that lived 
longer than 13  years also had a significantly smaller 
change in both the percent body fat increase, and per-
cent body lean decrease, than dogs living up to 13 years. 
We also showed that the rate of change in the fat to lean 
ratio was related to longevity where dogs living < 13 years 
had a larger change in fat mass compared to lean mass, 
than dogs living ≥ 13 years. Other studies have reported 
inconsistent associations between body composition 
variables at different ages and age at end-of-life [31, 32], 
including a moderate significant negative linear correla-
tion (r2 = 0.41) between lean fat ratio (LFR) and age in 40 
Labradors (age range 2.0 to 13.0 years) [32] although this 
was not corroborated in a similar study of 35 Labradors 
(age range 2.0 to 14.3  years) that showed a small posi-
tive correlation between FM and LM (r2 = 0.152) but no 
association of either FM or LM with age [31]. In the birth 
cohort group of 48 Labradors reported on earlier, annual 
DEXA scans performed near their date of birth from 
6 years of age to just prior to the end-of-life scan showed 
a highly predictive effect (P < 0.002) of fat and lean com-
position with early end-of-life. A high percent fat mass 
(PF) predicted an early end-of-life 1 year before end-of-
life whilst a high percent lean mass (PL) had a protec-
tive effect [33]. Unfortunately, the lack of a longitudinal 
study design (and use of repeated measures) in some of 
the previous studies prevented an evaluation of the effect 
of changes in body composition of individual dogs over 
their lifetime. Detailed knowledge of the impact on sur-
vival of changes in LM, FM and body weight mass (BW), 
the relationship between lean and fat across the lifespan 
of dogs and the effect of potential confounding variables 
is still lacking. The aim of the present longitudinal study 
was to investigate the effects of body composition and 
within-dog changes over time on survival in the previ-
ously described cohort of 39 adult Labrador retrievers 
using a repeated-measures prospective cohort design.
Methods
Study participants
The participating 39 neutered adult Labrador retrievers 
(12 males, 27 females) were all part of an original study 
designed as a clinical trial to test a novel energy restric-
tion mimetic in the form of a dietary supplement, man-
noheptulose. Details of the original study protocol 
have been previously described [19]; specific details are 
included to allow understanding of the objectives of the 
present study. All dogs were acquired from private breed-
ers or one United States Department of Agriculture-
inspected provider. One breeder provided 32 (82%) of the 
dogs1 from the mating of a total of 12 sires and 19 dams. 
There were four pairs of littermates, and two groups of 
three littermates amongst the 39 dogs, all six of these 
groups came from this one main breeder. For the 32 
dogs, from the single breeder, their husbandry (feeding 
and kennelling) and medical care (deworming and vacci-
nations) were kept consistent from birth and throughout 
early adulthood prior to them joining the study.
During the study all dogs were housed in indoor ken-
nels kept within an agreed temperature, humidity and air 
flow range. Additionally, each kennel had access to a par-
tially covered outdoor run. The dogs were provided with 
size-appropriate dog toys (for the indoor kennels) and 
equipment designed to provide environmental enrich-
ment was provided in the outdoor exercise areas: e.g. 
agility course apparatus, wading pools, a variety of dog 
toys and shaded areas. Twenty minutes of individual daily 
socialisation of all dogs took place with a qualified ani-
mal welfare specialist. Social groups of three to six dogs 
were exercised daily for a further 30 min minimum in the 
large gravel lined or grass outdoor exercise area. Compat-
ible groups of dogs had 24-h access to each other through 
their partially covered outdoor run that interconnected 
neighbouring kennels to allow for additional socialisa-
tion and exercise. Grooming was performed bi-weekly, 
bathing quarterly and each dog had access to regular 
veterinary care. The study design was approved by the 
Institutional Animal Care and Use Committee (IACUC) 
of Procter & Gamble (P&G) Pet Care (Mason, OH, USA) 
and the accommodation facility where the dogs were 
housed was accredited by the Association for Assessment 
and Accreditation of Laboratory Animal Care [19].
Study preparation and feeding
The dogs underwent an acclimatisation period from May 
2003 up to the start of the study on 16 July 2004. Dur-
ing this time the dogs were fed a nutritionally complete 
and balanced dry diet with 27.2% dry matter (DM) pro-
tein and 14.9% DM fat, see Adams et al. [19] for details. 
All dogs were surgically neutered in 2003 prior to the 
start of the study period. The mean and median age at 
neutering was 5.5  years (range 4.3–7.5  years) [19]; one 
male dog had been neutered at 4.4 years of age just prior 
to being recruited in May 2003. The dogs entered the 
study in 2004 at a median age of 6.5  years (± 0.9) and 
a mean BW of 28.7  kg (± 4.3  kg). During the study the 
aim was to maintain a body condition score (BCS) of 3 
based on a 5-point scale, although a score of 2 or 4 was 
accepted to avoid oscillating changes in feeding amounts 
and body weight. During the study, BCS was assessed by 
1 This is correction to what was reported in the earlier paper Adams et al. [19] 
of 33 dogs.
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trained staff on a quarterly basis to enable adjustment of 
daily food allowances to maintain a BCS between 2 and 4 
[19]. The daily food allowance could also be changed by 
the supervising veterinarian for medical purposes. The 
daily ration of food was weighed for each dog, divided 
daily into two equal portions and offered in stainless steel 
food bowls. At the start of the study on 16 July 2004 all 
39 dogs had been transitioned to a complete and bal-
anced dry study diet that incorporated nutritional com-
ponents found in  EUKANUBA® Senior Maintenance 
for large breed dogs2. The diet, which was fed during the 
entire study, had 26.7% DM protein, derived principally 
from animal based sources and 16.2% DM fat. The for-
mula included low glycaemic index grains, l-carnitine, 
the prebiotic Fructo-oligosaccharide and polyphosphate 
technology for reducing tartar build-up. Dogs were sep-
arated for feeding and food intake was recorded daily. 
Fresh water was constantly available using automatic 
adjustable water bowls mounted on the side of each 
housing unit [19].
Quality of life and end‑of‑life decisions
In addition to routine veterinary examinations, each 
dog was monitored daily by their animal welfare special-
ist and the animal husbandry staff; any health related 
concerns were brought to the attention of the attending 
healthcare staff (veterinarian and veterinary nurse). The 
healthcare staff would then initiate a quality of life (QoL) 
assessment. Assessments were conducted by animal wel-
fare specialists, animal husbandry staff and healthcare 
staff (attending veterinarian, veterinary nurses) to assess 
quality of life using a 10-point Likert scale ratings to 
assess food/water intake (hunger/thirst), pain/discom-
fort, mobility, hygiene, happiness and number of “good 
days” [34]. If the QoL was in decline then a consultation 
would take place within a defined team that included the 
study director and a number of veterinarians, both from 
the pet care division and from the wider company3 who 
were not involved in the study. The team were blinded to 
the dog’s identity and only the on-site attending veteri-
narian knew the identity. Decisions about administration 
of any medications, and end-of-life decisions, were made 
by the group based on the QoL assessment and the dog’s 
overall well-being and if it was compromised. The study 
director and the on-site veterinarian and veterinary nurse 
who worked at the Animal Care Center (ACC) where 
the dogs were housed, and the QoL assessment proto-
col, remained constant throughout the study period. Two 
of three company veterinarians also remained constant 
over the course of the study. The end-of-life decision was 
made with the attending veterinarian, veterinary nurse, 
study director, and a minimum of one non-ACC vet-
erinarian. The purpose of this approach was to maintain 
objectivity in making end-of-life decisions by balancing 
any personal bias from the attending veterinarian and/or 
veterinary nurse with the expertise from licensed veteri-
narians (not involved in the study) and the study director. 
The on-site attending veterinarian was allowed to make 
an immediate end-of-life decision if there was a rapid 
deterioration in any dog’s health.
BW and body composition
BW was measured every 2 weeks and whole body com-
position measures were obtained during the acclima-
tisation period in 2003 and annually from 2005 to 2015 
using a DEXA scanner (Model Delphi-A, Serial No. 
70852; Bedford, MA). Dogs were fasted for a minimum 
of 12 h prior to being weighed and sedated for the DEXA 
scan using a pre-anaesthetic combination of aceproma-
zine  (PromAce® Injectable, Fort Dodge, Fort Dodge, IA; 
0.55 mg/kg intramuscular injection) and atropine sulfate 
(Med-Pharmex, Pomona, CA; 0.04 mg/kg subcutaneous 
injection). Dogs were then anaesthetised via a secured 
intravenous catheter to administer propofol  (Propoflo®, 
Abbot Labs, Chicago, IL; 7 mg/kg). Dogs were then intu-
bated with an endotracheal tube, to deliver 100% oxygen 
and routine anaesthetic monitoring was performed. Dogs 
were positioned in sternal recumbency with hind limbs 
extended caudally and a calibration was completed prior 
to each DEXA scan, after which measurements were 
taken using the whole body scanner (single-beam mode). 
Oxygen was continued for several minutes after the scan 
was completed before moving the dogs to a recovery 
cage; the endotracheal tube was removed once the swal-
lowing reflex was regained.
Data analysis
Outcome variable and risk factors
Labrador coat colour was black, yellow or chocolate, sex 
was either female or male and all were neutered prior to 
the study commencing in mid-July 2004. Age at neuter-
ing and age at start of study were recorded as well as the 
2 At the time of the study’s commencement in July 2004 the brand 
 EUKANUBA® was owned by Procter and Gamble, Cincinnati, OH, USA. 
On January 1st 2015 the brand was purchased for Europe only by Spec-
trum Brands, Middleton, WI, USA and continues to be sold under the name 
 EUKANUBA® in Europe.
3 Assessments were conducted by animal welfare specialists, animal hus-
bandry staff and healthcare staff (attending veterinarian, veterinary nurses) 
to assess quality of life using a 10-point Likert scale ratings to assess food/
water intake (hunger/thirst), pain/discomfort, mobility, hygiene, happiness 
and number of “good days”. When the dog was having more “bad days” than 
“good days” then the attending veterinarian convened a panel to discuss an 
end-of-life decision; original concept, Oncology Outlook, by Dr. Alice Vil-
lalobos, Quality of Life Scale Helps Make Final Call, VPN, 09/2004; scale 
format created for author’s book, Canine and Feline Geriatric Oncology: 
Honouring the Human-Animal Bond, Blackwell Publishing, 2007. Revised 
for the International Veterinary Association of Pain Management (IVAPM) 
2011 Palliative Care and Hospice Guidelines.
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height at the shoulders in centimetres and as a categori-
cal variable based on tertiles of the data. Whole body 
composition measures obtained from the DEXA scans 
included total body mass as the fasted BW just prior to 
the scan (kg), total FM (kg), total LM (kg), PF and PL. 
The LFR was estimated as LM divided by FM. For DEXA 
derived variables at specific ages, the time points used 
were 8, 10 and 12 years of age based on including obser-
vations ± 0.5  years from the exact age; however, for the 
8-year time point, two observations of 7.4 years and two 
observations of 8.8  years were included to maintain a 
complete data set; for the 10-year time point, one obser-
vation of 9.1 years was included.
For continuous variables, mean [± 1 standard deviation 
(SD)] are presented as descriptive statistics. Dogs were 
previously classified into three groups derived from ter-
tiles of lifespan data: ‘expected’ (n = 13) when they experi-
enced a lifespan of ≥ 9 to ≤ 12.9 years, ‘long’ (n = 15) when 
they experienced a lifespan between ≥ 13 and ≤ 15.5 years 
and ‘exceptional’ (n = 11) when they achieved ≥ 15.6 years 
and beyond, as presented in a previous publication [19]. 
The value of 15.6 years to describe the start of an excep-
tional age for the Labradors was defined as the breed’s 
typical or average lifespan of 12 years, as determined by 
a consensus group of canine experts, plus 30% [19, 35]. 
Percent body fat against age and percent body lean against 
age are presented by longevity category in polynomial 
smooth plots for illustrative purposes (all dogs in the pre-
sent analysis had reached end-of-life compared to our ear-
lier DEXA analysis where 26 dogs in the long (n = 15) and 
exceptional (n = 11) groups were still alive [19]).
Statistical analyses
Kaplan–Meier survival curves were used to examine 
the effect of sex, coat colour and height at shoulder on 
survival times. Survival analysis using Cox proportional 
hazards regression was performed to estimate the effect 
of potential predictors on “time to end-of-life”. The vari-
ables age at study start, sex, coat colour, shoulder height, 
starting, maximum and minimum BW during the study, 
age at minimum BW during study, age at maximum BW 
during study, and the body composition variables (at spe-
cific ages of 8, 10 and 12 years and also as linear changes 
over 2-year intervals for 8–10  years, 10–12  years) were 
examined for potential influence on the age of end-of-life. 
The selection of the variables for potential inclusion in 
a full model included a two-stage process: (1) univariate 
Cox regression analysis selected variables with P < 0.25 
followed by (2) correlation (Pearson’s correlation coef-
ficient = r) analysis to select variables that did not show 
collinearity (r < 0.7). Time at risk was measured in days 
from study start in July 2004 until end-of-life. For the 
main model, variables with data available for all 39 dogs 
were examined for potential influence on overall survival. 
The final Cox regression model was selected based on 
step-wise reduction from the full model until only varia-
bles with P < 0.05 remained. All models were adjusted for 
clustering of dogs within litter. All two-way interactions 
of the main effects were tested.
Validation of the model
Model diagnostics were performed on the final model 
evaluating the assumption of proportional hazard using 
the test for proportional hazards based on the Schoenfeld 
residuals for each variable in the model, the goodness-
of-fit test and by graphing the survival function for the 
mean of all covariates in the final model to illustrate the 
impact of an increased hazard due to a covariate of inter-
est [36, 37]. Sensitivity analyses were performed in three 
ways: (i) excluding the observations that were outside 
the ± 0.5 year range for ages 8 (n = 4) and 10 (n = 1); (ii) 
including data at 12  years (± 0.5  years) into the model 
which reduced the number of dogs included to 37; and 
(iii) taking the monthly average BW change into account 
as a time-varying covariate. The level of significance for 
all statistical tests was set at P < 0.05. Statistical analysis 
was done using Stata SE v14.2 (Stata Corporation).
Results
Descriptive statistics
DEXA data included 12 calendar years (2003, 2005–
2015) of which the eleven years within the study period 
(2005–2015) were included in this analysis. Age at DEXA 
scans within this study ranged from 6.2 to 17.0 years. All 
39 dogs had DEXA recorded at 8, 9 and 10 years of age 
and 37 dogs also had a DEXA scan at 12 years (Table 1). 
One dog was found dead in its kennel and the other 38 
dogs underwent euthanasia due to morbidities affecting 
their quality of life; the exact date of the end-of-life was 
used as the end point of the study (Table 2). 
Body composition varied for all dogs up to their end-of-
life. The mean minimum and maximum body weight dur-
ing the study (irrespective of age or time of weight) were 
24.8 kg (± 3.6) and 34.7 (± 3.9), respectively. The dog that 
was heaviest during the study reached a maximum BW of 
44.0 kg approximately 1 year into the study at 6.8 years of 
age; he was also the tallest dog (61 cm shoulder height) 
and he died at 13.2 years of age. The mean individual BW 
change during the study was 9.9 kg (± 3.0). The dog that 
was lightest during the study reached the minimum BW 
of 17.5  kg at 14  years of age; she then slowly increased 
her body weight to 22 kg at her death at 17 years of age; 
she was one of the two smallest dogs (49.5  cm shoul-
der height). The body weight at 10  years and the body 
weight change between 8 and 10  years was moderately 
correlated (Pearson correlation r = 0.48) (Fig.  1) The 
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mean individual minimum BW for all 39 dogs was sim-
ilar to that for the 19 dogs that had > 10  kg BW change 
during the study, although these 19 dogs lived some-
what longer with a median age of 14.0  years at end-of-
life; eight of these 19 dogs were in the exceptional group 
(lived > 15.5  years) and included three of the four dogs 
that lived > 17 years.
The PF against age by longevity category is presented 
in Fig. 2. Between 7 and 10 years, expected dogs showed 
an average increase in PF of 4.2% per 1 year increase in 
age, whereas long and exceptional dogs showed average 
increases in PF of 3.2% and 1.6%, respectively, per year; 
the difference between the longevity groups was statisti-
cally significant when evaluated using a linear regression 
model (P = 0.02). The decrease in PL by age mirrored 
the gain in PF (Fig. 3). The mean values (± 1 SD) of LM 
and FM are shown with the LFR and BW by age (Fig. 4a). 
Only seven dogs had a positive change in LFR from 8 to 
10  years of age. Mean fasted BW values, measured just 
prior to each DEXA scan, followed the same pattern as 
fat mass changes by age but were ~ 22 kg higher at each 
age until ~ 12  years age, after which the difference was 
smaller. The pattern of mean values (± 1 SD) of PL and 
PF (Fig. 4b) were similar to those for LM and FM.
Survival analysis
In total, the 39 dogs contributed 105,636  days at risk 
during the study, with a median of 2715  days at risk 
and a range from 929 to 4072 days. Based on univariate 
Cox regression analysis, 30 variables with P ≤ 0.25 were 
checked for collinearity, resulting in 9 variables eligible 
for inclusion in the Cox regression modelling: sex, height 
at shoulder (49.5 to < 53, 53 to 55.9 and 56.0 to 61.0 cm), 
coat colour, age at study start, BW at 8 and 10  years of 
age, change in LM from 8 to 10 years, LFR at 10 years and 
change in LFR from 8 to 10 years.
Backward elimination from a full model of nine varia-
bles resulted in a final model that included four variables: 
BW at 10 years of age, change in LM from 8 and 10 years, 
change in LFR from 8 and 10 years and age at study start 
(P ≤ 0.002, Table  3). There was an increased hazard of 
dying for every kg increase in BW at 10 years of age such 
Table 1 Demographic and  descriptive data for  39 dogs 
followed until  end-of-life, including  body composition 
data
Variable Category N %
Sex Male 12 31
Female 27 69
Colour Black 14 36
Chocolate 3 8
Yellow 22 56
Variable N Mean (± SD)
Height at shoulders (cm) 37 55.0 (3.0)
Age at study start (years) 39 6.8 (0.9)
Age at neutering (years) 39 5.5 (0.8)
Age at end-of-life (years) 39 14.2 (2.0)
Body weight at study start (kg) 39 28.7 (4.3)
Body weight at 8 years (kg) 39 30.4 (4.0)
Body weight at 10 years (kg) 39 32.1 (4.6)
Body weight at 12 years (kg) 37 31.5 (4.0)
Body condition score at 8 years 20 3.3 (0.4)
Body condition score at 10 years 39 3.4 (0.5)
Body condition score at 12 years 37 3.4 (0.5)
Total fat mass (%)  (ndogs = 39) 275 32.8 (5.6)
Total fat mass (kg)  (ndogs = 39) 275 10.1 (2.7)
Total lean mass (%)  (ndogs = 39) 275 64.2 (5.5)
Total lean mass (kg) 275 19.5 (2.7)
Change lean mass 8 to 10 years 39 − 392.4 (741)
Ratio lean:fat (g) 275 2.1 (0.6)
Change lean:fat 8 to 10 years 39 − 0.3 (0.4)
Table 2 Causes of end-of-life for 39 dogs
Cause of end-of-life for the last 5 dogs were not included in Adams et al. (ref. [19]) and have been added to this table in italics




Cancer 16 (41%) 13.9 (9.7–17.9) 5 hemangiosarcoma, 2 hepatocellular carcinoma, 1 mast cell tumour + 1 mast cell tumour, 
2 urinary tract cancer and 1 each of lymphosarcoma, osteosarcoma, plasma cell tumour, 
adenocarcinoma and prostatic cancer
Gastrointestinal disease 4 (10%) 13.5 (12.8–14.1) 1 each of mega-oesophagus, gastrointestinal (GI) inflammation, gastric dilatation volvulus 
and found dead in kennel [enteritis, colitis + protein-losing enteropathy (PLE)]
Heart, kidney, liver and/
or pancreas disease
5 (13%) 15.2 (13.6–17.6) 2 chronic kidney disease, 1 myocardial fibrosis + 1 other heart disease + 1 renal, GI, liver and 
pancreatic pathology
Musculoskeletal 8 (20%) 13.8 (12.1–15.8) 7 osteoarthritis + 1 intervertebral disc disease
Other 3 (8%) 13.9 (11.7–15.2) 2 seizures + 1 septicaemia
Quality of life 3 (8%) 15.8 (14.8–17.0) With no proximate cause identified on post-mortem examination
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Fig. 1 The relationship between body weight at 10 years and the body weight change between 8 and 10 years for 39 Labrador retrievers (Pearson’s 
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Fig. 2 Polynomial smooth plot of average percent fat (95% CI) by age for each longevity category. Groups are based on tertiles of survival: 
expected (red line), long-lived (white line) and exceptional (orange line) for 39 dogs including all available DEXA data. Mean percent fat increased 
until approximately 10 years of age for dogs in the expected and 11 years for the long-lived groups and up to 12 years of age for exceptional group. 
After these ages, the percent fat stabilised
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that for each additional kg of BW at 10 years, dogs had 
a 19% higher hazard (HR = 1.19, P = 0.004). For both 
the change in LM and change in LFR variables, it was 
protective (lower hazard of dying) to have a higher LM 
and/or lower FM at 10 years of age compared to 8 years, 
although the HR for change in LM was very close to 1.0. 
For age at study start, older dogs had an increased hazard 
(HR = 1.69, P = 0.008).
The survival function of the final Cox model, evaluated 
at the mean value of the covariates, was plotted by strati-
fying the dogs based on the mean BW value of 32 kg at 
10 years of age (Fig. 5). Four of five of the longest lived 
dogs (age at end-of-life > 16.6  years) had a BW < 32  kg 
at 10  years of age. Of the five dogs that died before 
12.6  years of age (excluding two potential outliers that 
died at the youngest ages and earliest in the study), four 
had a BW ≥ 32  kg at 10  years of age. The longest living 
dog in the study, a male living to 17.9 years of age, was 
7.1 years of age at the study start and at 10 years of age 
he had a BW of 28.1 kg, LM of 21.4 kg and FM of 5.8 kg, 
respectively, with a LFR of 3.7 (Fig. 6).
None of the two-way interactions were significant. 
The assumption of proportional hazard was not violated 
(P ≥ 0.2 for Schoenfeld residuals for each variable and a 
global P = 0.6; P = for the goodness-of-fit tests for five 
quantiles of risk). Two potential outlying observations 
were detected, and these were the two dogs that died at 
the youngest ages and earliest in the study (one of these 
dogs was also influential and one had very low influ-
ence). Rerunning the final model excluding these two 
dogs resulted in small changes (< 9%) for all point esti-
mates of the HR. There were three additional dogs with 
the highest delta-beta residuals that could be considered 
to be influential. It appears that it was four rather heavy 
dogs that died fairly young that had highest influence; 
conversely, the other potential outlier that died at the 
youngest age had a BW of 25.5 kg at 10 years of age and 
showed very low influence. Removing the four dogs with 
the highest delta-betas resulted in similar small changes 
(< 7%) to the HR point estimates.
The sensitivity analyses yielded the same variables in 
the final model with approximately similar estimates 
of effect. Excluding the observations that were outside 
the ± 0.5  year range for ages 8 (n = 4) and 10 (n = 1) 
resulted in a small alteration in the HR for the change 
in LFR from 8 to 10 years of age. Adding BW at 12 years 
of age to the final model reduced the number of dogs 
included to 37 and changed the HRs for the other vari-
ables by < 15% and the variable itself was not significant 
(P = 0.6). Including average monthly BW as a time vary-
ing covariate did not indicate that monthly changes in 
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Fig. 3 Polynomial smooth plot of average percent lean (95% CI) by age for each longevity category. Groups are based on tertiles of survival: 
expected (red line), long-lived (white line), and exceptional (orange line) for 39 dogs including all available DEXA data. The change in percent lean 
showed a similar but mirrored pattern to percent fat (Fig. 2) with a decrease in percent lean until approximately 11 years for the expected and 
long-lived groups and 12 years for the exceptional group, respectively. After this, the percent lean stabilised
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Discussion
The present longitudinal study reports on BW and body 
composition factors related to age at end-of-life in a 
cohort of 39 adult Labrador retrievers. There are few 
studies that report on age related changes in body com-
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Fig. 4 a Lean mass, fat mass, body weight and lean to fat ratio by age. The mean values and ± 1 standard deviation (bars) for lean mass (green line 
with dark red bars), and fat mass (grey line with orange bars), and mean body weight (blue line) as weight in grams on left y-axis and the lean to 
fat ratio (red line) on right y-axis, by age for 39 Labradors followed from a median age at the start of the study of 6.5 years until end-of-life. b Lean 
percent and fat percent by age. The mean values and ± 1 standard deviation (bars) for lean percent (red line with blue bars) and fat percent (orange 
line with green bars), by age for 39 Labradors age showed a similar pattern as lean and fat mass in a 
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studies of people over 80  years of age, and factors that 
affect these changes such as physical activity. To our 
knowledge, no other study has reported similar data over 
adult life in dogs and adjusting for potential confound-
ing factors. Investigating dogs of the same breed which 
received similar husbandry and feeding regimen con-
sistently from adulthood to end-of-life poses a unique 
opportunity to study factors not related to variation in 
husbandry, exercise, health care, etc. which is inevitable 
when studying privately-owned dogs. Other studies that 
reported on longevity data from veterinary practices, 
insurance companies and owner surveys [5, 6, 20–22, 
38] therefore provide less useful detailed comparisons 
as they will be inevitably biased by unmeasured factors 
Table 3 Results of univariable and multivariable Cox proportional hazards regression for 39 dogs
Body weight (BW), change in lean body mass and change in the ratio of lean to fat mass during middle age (~ 8 to 10 years of age) were all significant independent 
predictors of survival in the final regression model
Variable
BW at 10 years Change in lean mass 8 
to 10 years




 β (SE) 0.104 (0.045) − 0.0004 (0.0002) − 0.82 (0.48) 0.23 (0.20)
 HR (SE) 1.11 (0.05) 0.9996 (0.0002) 0.44 (0.21) 1.25 (0.25)
 HR 95% CI 1.017–1.210 0.9991–1.0001 0.17–1.13 0.85− 1.84
 P-value 0.020 0.12 0.09 0.25
Multivariable analysis/adjusted model
 β (SE) 0.170 (0.059) − 0.0012 (0.0003) − 1.43 (0.45) 0.53 (0.20)
 HR (SE) 1.19 (0.07) 0.9988 (0.0003) 0.24 (0.11) 1.69 (0.34)
 HR 95% CI 1.06–1.33 0.9982, 0.9993 0.099–0.582 1.15–2.50
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note: loglog based CI
Fig. 5 The survival function at mean values for covariates by body weight category at 10 years. The survival function with 95% confidence limits for 
the main Cox model (including the 4 variables: body weight at 10 years, change in lean mass from 8 to 10 years, change in lean to fat ratio from 8 to 
10 years of age) and age at study start, evaluated at the mean value of the covariates and stratified by the mean body weight of 32 kg at 10 years of 
age. < 32 kg (blue with green CI) and ≥ 32 kg (brown with yellow CI)
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related to diet, exercise, general husbandry and veteri-
nary care as well as a lack of consistency of these factors 
over time. In fact, the suggested positive effects of con-
sistent husbandry for the dogs in the present study is in 
line with findings from longitudinal human cohort stud-
ies reporting that healthy biological ageing was affected 
by lifetime protective factors including maintenance of 
normal weight across adult life, good prior health and 
positive health behaviours [39].
Early life environments including intrauterine, neo-
natal and early life have been reported as important for 
later life mortality [40] but it has also been suggested that 
there is no single factor or time point responsible for suc-
cessful ageing but that ageing is due to lifelong accumula-
tion of damage [41]. The ageing process leads to a decline 
in function of most organs and tissues, and includes sar-
copenia, cognitive decline, diabetes, osteoarthritis and 
may be similar in dogs and humans, although the rela-
tive risk for individual diseases is not always shared [3]. 
Sarcopenia offers the potential for interventions to off-
set its commencement, progression or severity. Further, 
the co-existence of reduced muscle mass and increased 
fat mass, so called sarcobesity (sarcopenic obesity), has 
been acknowledged as an unfavourable relationship 
between lean and fat mass [29]. In humans the interest 
in sarcopenia lies with the amount of muscle mass and 
especially its strength [42, 43]. With muscle performance 
being clinically relevant for the frail and elderly there is 
less focus on the fat mass, aside from being cognisant of 
sarcopenic obesity. We therefore see reference to muscle 
mass, and particularly strength, rather than expression of 
the LFR in human studies (personal communication Dr. 
Emanuele Marzetti, Policlinico Universitario Agostino 
Gemelli, Italy, with DMM).
The current canine study does not address factors that 
may be important before ~ 6 years of age; however, it does 
show that, given that these dogs survived to adulthood, 
BW, LM, FM and LFR were important even in older age. 
This means that the status of a dog at a young age is not 
the only relevant time period for longevity as supported 
by the fact that BW at the study start alone was not sta-
tistically significant and thus not predictive of longevity. 
Instead, this study reports that body weight at late middle 
age (~ 10 ± 0.5 years of age) for these dogs was a predic-
tor of longevity. An important advantage of this predictor 
is that it is easily evaluated in dogs hence supporting clin-
ical relevance of the study finding, to maintaining and/or 
improving health of the ageing Labrador. Mean BW over 
time for the dogs in the present study was similar to that 
of the 24 ‘control’ dogs from the 1987 birth cohort who 
consumed more food than needed [13, 17, 33] and yet the 
dogs in the present study lived significantly longer [18]. 
This suggests that BW alone may not be a good predictor 
of survival/longevity; however, the earlier study did not 
report height at shoulder, making it difficult to evaluate 
the effect of the phenotype and size of the dogs. Future 
birth cohort studies that record potential confounders, 
including measures of physical activity, are needed to 
show whether early age status has a more profound effect 
on longevity than middle age status.
Few studies have investigated body composition and 
ageing in dogs and most have only looked at age at end-
of-life and body composition measured on individual 
dogs at different ages [31, 32] and did not use repeated 
measures on dogs over time. Interestingly, the mean LM 
and change in LM between 9 and 13 years seen in the pre-
sent study was similar to the ‘control’ fed (i.e. more gen-
erously fed) Labradors in the diet restriction study [13, 
17, 33], albeit the dogs in the present study lived signifi-
cantly longer. The dogs in the present study gained ~ 2 kg 
mean FM from 8 to 10 years of age whereas the ‘control’ 
dogs maintained fairly stable mean FM over these ages 
[13]. After age 11 years of age, our Labradors experienced 
an almost linear reduction in mean FM whereas the ‘con-
trol’ Labradors experienced an increase in FM of ~ 3 kg 
from 11 to 12 years of age (the last data point presented 
for this group) [13, 17]. The dogs in the present study 
had a relatively high mean PF throughout the study. For 
example, at 8  years of age the fat percent was 28% (for 
expected and exceptional dogs) and 30% (for long-lived 
Fig. 6 The longest living dog in the study pictured at 17 years of 
age illustrating the high level of healthspan accomplished by this 
dog. This was a male black Labrador called Utah, height at shoulders 
55.9 cm, age at study start: 7.1 years, age at end-of-life 17.9 years. 
Body weight at 10 years = 28.1 kg, weight the month before 
end-of-life 28.8 kg, lean and fat body mass at 10 years: 21.4 and 5.8 kg, 
respectively (image courtesy of  EUKANUBA®, UK)
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dogs), respectively, and yet these dogs lived longer than 
the Labradors in the diet restriction study [17, 18]. This 
implies that relative fat mass may not be a crucial factor 
for longevity and raises the question of whether having 
a certain amount of FM in relationship to overall BW at 
a certain age is not strongly related to longevity. In fact, 
the variable fat percent at 10  years, with almost perfect 
correlation to lean mass percent at 10  years (data not 
shown), was offered to the full Cox regression model 
based on passing the criteria for univariate analysis and 
correlation analysis, but failed to remain in the model 
once other variables were accounted for. For FM, LM and 
fat percent over age, the pattern of fat mass change differs 
between our study and the diet-restriction diet. Further 
comparisons between the two studies are limited due to 
differences in recruitment age and study design. Another 
aspect of diet restriction is that it might reduce life qual-
ity if the dog is too hungry. To our knowledge there are 
no studies that have investigated stress, behaviour and 
life quality in hungry/calorie-restricted dogs. However, 
the genetic link between increased BW, obesity and 
increased appetite in Labrador and flat coat retrievers 
has been reported as strongly related to a deletion of the 
gene POMC via a change in the two peptides β-MSH and 
β-endorphin that are potent appetite regulators [44, 45]. 
The mode of action has been suggested as either through 
an additive [44] or recessive effect [45]. Knowledge of the 
genetic map of a Labrador retriever may aid in early pre-
vention actions, in particular for dogs genetically prone 
to becoming overweight, and may also support breeding 
strategies to reduce the genetic predisposition for over-
weight and obesity in Labradors. Unfortunately, there 
was no genetic testing performed on the dogs in this 
study so the POMC status is unknown. It could be specu-
lated that as all dogs in the present study were assessed 
daily by the welfare specialist to ensure life quality, it may 
be assumed that either none of the dogs had the POMC 
deletion or they were managed in a way that removed any 
negative effect of this deletion. As it has been suggested 
that dogs can influence the type and quantity of food 
offered to them by the owners and therefore access more 
food than optimal [46], the study design in the present 
study might have prevented an effect of a genetic muta-
tion as any manipulation of the staff was likely low. Any 
future studies may establish the relationship between 
adequate BCS, hunger-management and life quality. The 
insights from the present study offer potential key factors 
to address to limit the growing problem of overweight 
and obese Labradors and promote expanded healthspan. 
The results also have potential cross-breed and cross-
species applications.
The findings that both change in LM and change in LFR 
are related to survival have not previously been reported, 
although there are reports on one or the other factor 
having an impact [31, 32]; however, these earlier stud-
ies did not include dogs surviving to an exceptional age 
as reported here. The present study indicates that there 
are intricate relationships amongst the body composi-
tion variables and age, as shown by the final Cox model 
which included the change in LFR from 8 to 10 years of 
age, change in LM from 8 to 10  years, BW at 10  years 
and age at study start as factors associated with survival. 
Change in LM and FM with age were previously reported 
by the birth cohort group of 48 Labradors; estimating 
the mean LFR by age for the birth cohort dogs was per-
formed using published mean age-specific values of lean 
and fat. The ‘restricted’ group had a LFR > 4.0 between 6 
and 10 years of age and this was considerably higher than 
the dogs in the present study who had mean LFR < 3.0 
which were more similar to the ‘control’ group; however, 
the dogs in the present study had a MST of 14.0  years 
that was significantly longer than the ‘control’ group 
which had a MST of 11.1  years. It is still not clear why 
the different cohorts of Labradors show such different 
phenotypes and lifespans. Indeed, none of the 48 birth 
cohort Labradors reached or exceeded an exceptional 
longevity of 15.6 years of age as compared to 28.2% of our 
present cohort of 39 dogs [18]. It may be argued that the 
‘restricted’ group, with a mean FM of only about 3.5 kg 
(or ~ 16% body fat) at 6 years, and 4.5 kg (or ~ 19.5% body 
fat) at 8 and 10  years of age, with a MST of 12.9, may 
have been too thin. For comparison, our dogs classified 
as expected longevity had a median BCS of 3 (range 1–5; 
n = 9) at 8  years; for the exceptional group the median 
BCS at 10 years was also 3 (range 2–4.5; n = 11).
The decline in LM over time that commonly occurs 
with ageing calls for developing strategies to combat this 
loss. Through adopting for our dogs a life course per-
spective to healthy ageing [47] future research can look 
at early-life intervention strategies (“windows of oppor-
tunity”) that continue through all life-stages aimed at 
helping to offset or slow down sarcopenia developing. 
Ageing dogs are capable of metabolising dietary protein, 
providing us with simple feeding strategies that could 
help offset the development of sarcopenia. Whole-body 
protein turnover has been recorded in both young and 
ageing Beagles, average ages of 2 and 8 years respectively, 
fed isocaloric diets with 17.4, 25.8 and 34.0% protein on 
a DM basis over an 8-week feeding trial [48]. Rates of 
whole-body protein synthesis (WBPS) and whole-body 
protein degradation (WBPD) were positively correlated 
with dietary protein intake. Maintaining a “high” protein 
level (at least > 24% on an “as fed” basis or > 25% of calo-
ries) as provided to the dogs in the current study, would 
be practical for support of LM in healthy ageing dogs 
given that many other studies have found an age-related 
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decline in endogenous protein synthesis [12, 49]. More 
recent data suggests that protein intake should be aimed 
at a minimum of 50% more than adult requirements, 
but further research is needed into what constitutes an 
optimal level in our healthy ageing dogs [50]. Additional 
reviews on protein and ageing have highlighted une-
quivocally that protein restriction is unnecessary in our 
healthy, older dogs [49].
As a result of the small sample of dogs with many 
observations recorded over ~ 10  years in the present 
study, some peculiarities emerged from the statistical 
analysis. For example, adding sex as a known confounder 
did not change the variables included in the final model, 
gave similar estimates of effect and sex was not signifi-
cant. For simplicity, we therefore removed sex from the 
final model although it may be argued that a known con-
founding variable should be kept albeit non-significant. 
BW is easy to measure, although less clinically relevant 
to assess than lean and fat mass. As DEXA scans are 
not standard clinical equipment we need other reliable 
tools replacing DEXA scans in the clinic setting. Studies 
have reported on methods to estimate fat and/or muscle 
mass in dogs [51], for example, comparisons have been 
made between body fat estimations using DEXA, deute-
rium oxide, BCS (visual + palpation), and morphomet-
ric measurements in healthy dogs [52]. This initial study 
on 23 dogs showed an overall high correlation between 
DEXA scan, BCS and morphometric measurements, but 
as within dog estimates varied quite significantly (> 5 to 
10% difference), it would be advisable to repeat this study 
in more dogs of various types and breeds to establish the 
accuracy of the BCS and morphometric measurements. 
Regular veterinary assessment of both the BCS and 
muscle condition score (MCS) should be undertaken to 
monitor overall body composition, namely adipose tis-
sue, but also muscle mass. Relying on just taking body 
weight measurement could potentially mislead the clini-
cian to erroneous conclusions, especially if there is sar-
copenic obesity with a parallel increase in body weight, 
thus rendering this measure as rather insensitive [27]. 
In fact, the World Small Animal Veterinary Association 
(WSAVA) have developed a practical nutritional assess-
ment toolkit that can help evaluate each patient for both 
BCS and MCS [53], and other comprehensive reviews of 
ageing dogs are available [49].
Previous studies have reported on the predictive abil-
ity of the body composition variables from DEXA scans 
performed at the time of end-of-life and at 1 and 2 years 
before end-of-life. It was not possible to replicate this 
type of analysis in the present study as DEXA scans were 
not performed at the same ages for all the dogs. However, 
in the present study the dogs were recruited in middle 
age and then initially acclimatised to reduce their BW 
before starting the study so as to reach an optimal tar-
get BCS of 3 on a 5-point scale. This BW reduction was 
required for the majority of dogs before entering the 
study. The increased healthspan and longevity reported 
for these dogs indicates that rather late efforts to control 
BW and FM is likely to have a positive effect on the dog’s 
longevity. This should be encouraging to owners, as well 
as their veterinarian, when implementing weight reduc-
tion strategies having realized at a rather late stage of 
adulthood that their dog is too heavy for their size.
For privately owned dogs, the decision of euthanasia 
is often based on a combination of factors relating to the 
dog, the owner(s) and the veterinarian [54]. In the pre-
sent study the decision was made by a team that evalu-
ated the dogs’ welfare and quality of life, hence removing 
some of the variation in the decision making process; we 
suggest that this was likely to result in a more accurate 
age of end-of-life that reflected the age when the dog’s life 
needed to end based only on health and welfare.
The dogs in the present study received a balanced com-
mercial ‘senior’ diet. Studies are being performed to iden-
tify modulators that can be added to a diet to prolong life. 
For example, recent studies have investigated the possi-
bility of extending life span though the immune modula-
tor rapamycin [3], an inhibitor of the mammalian target 
of rapamycin (mTOR) signalling pathway and which has 
demonstrated an effective anti-ageing effect in various 
model organisms (yeast, worms, flies, mice) [55–58]. The 
mTOR signalling pathway serves as a central regulator of 
cell metabolism, growth, proliferation and survival [59], 
it is also inhibited by calorie restriction [60]. Another 
candidate for clinical testing is metformin, a biguanide 
antihyperglycaemic agent [3]. The role of the gut micro-
biota is also being investigated as a potential strategy 
for longevity extension through exploitation of the bidi-
rectional communication system of the gut-brain-axis 
(GBA) [61], specially targeting the effect of age-related 
chronic inflammatory processes, inflammageing (as pre-
viously mentioned), for example to reduce its impact on 
muscle ageing, the focus being firmly aimed at sarcopenia 
[62].
A recent publication that also evaluated data from this 
present cohort of 39 Labradors, together with a second 
cohort of 41 Labradors, reported finding a profile of 
changes indicative of inflammageing [9]. While this study 
did not explore any association of inflammation and body 
composition measures in these ageing dogs it does help 
highlight those pathways that may be valuable for devel-
oping preventive and therapeutic interventions against 
muscle ageing in dogs. Although these prospects are 
promising, the present study indicates that consistency in 
feeding, activity and exercise and health care were key to 
a long healthspan in these dogs.
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One potential limitation of this study is that the 
cohort consisted of dogs that were recruited, at the 
start of the study in July 2004, at a median age of 
6.5  years (range of ages from 5.4 to 8.5  years), and as 
such constitute a sample of the Labrador population 
that had survived to adulthood. As the dogs had to sur-
vive and be healthy at recruitment, some caution must 
be applied when extrapolating to survival from birth. 
However, this is somewhat contradicted by the find-
ings in the study: the age of the dog at the start of study 
was negatively associated with age at end-of-life: The 
study suggests that there was not a linear survivorship 
effect by enrolling dogs aged > 5 years; in fact, the final 
model suggests that the older the dog at enrolment, the 
greater the hazard of end-of-life. It may be that there is 
a threshold for longevity so that if the dog survives to a 
certain age it is likely to live longer. This thought is in 
line with the concept of population heterogeneity pro-
posing that if there is variation in the underlying frailty 
within a population (i.e., demographic heterogeneity) at 
the individual-level, at each age individuals with higher 
frailty to a specific factor are more likely to die. Hence, 
the impact/importance of this factor may decrease over 
time as more resilient individuals are left. This differ-
ential selection can cause different mortality patterns 
for the population as a whole compared to individuals 
[63]. Ideally, individuals should be randomly selected to 
studies to account for the individual-level heterogene-
ity [64]. In this study the life-style and environmental 
factors were kept similar to all individuals, which may 
reduce their influence on the population longevity.
Another aspect to consider is that 32 of the dogs were 
recruited from the same breeder and many were lit-
termates. The Cox regression model took the cluster-
ing of dogs within litters into account. Adding breeder 
to the final model as a fixed effect was non-significant 
(P = 0.83, data not shown). Running the final model 
separately for dogs from the same breeder (n = 32) gave 
similar results as when including all dogs, as expected 
by the large contribution of dogs. However, the point 
estimate HR for age at start of study was lower albeit 
no longer statistically significant. On the other hand, 
when running the model for the dogs from other breed-
ers (n = 7), the HR for age at start of study was larger 
(3.8) as was HR for BW at 10 years (1.29) whereas the 
HR for change in LFR was somewhat smaller (0.02; data 
not shown) but explanatory variables were non-signifi-
cant due to the low number of dogs. This suggests that 
the breeder contributing with many dogs had its largest 
impact on longevity by potentially reducing the effect 
of age at recruitment and BW at 10 years.
Conclusions
These results suggest that for this cohort of Labra-
dor retrievers even rather late-life control efforts, 
after 8  years of age, on body weight and the relation-
ship between body lean and fat mass, influenced sur-
vival. Such “windows of opportunity” can be used to 
develop healthcare strategies that would help promote 
an increased healthspan in dogs.
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